ENAGenomicsClevenger Laboratory, Massey Cancer Center, Virginia Commonwealth Universityhttps://www.ebi.ac.uk/ena/browser/view/PRJNA320900Homo sapiensThe hormone prolactin is implicated in the pathogenesis of breast cancer, and a subset of prolactin-induced gene expression is mediated by HDAC6 activity. The NSAID, bufexamac, is a fairly specific inhibitor of HDAC6 and HDAC10. We used bufexamac in combination with prolactin treatment in MCF7 cells to determine differential expression under these conditions. Overall design: MCF7 cells were serum starved for 24 hours prior to treatment with bufexamac and/or prolactin, and subsequent RNA extraction.xref:PubMed:27358110ENAfalseHomo sapiensGene expression data from MCF7 breast adenocarcinoma cells treated with prolactin and/or bufexamac2025-09-242016-05-08PRJNA320900GSE81217960627358110